FindTrial
Sign In

MK-3415A

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Clostridium Difficile Infection

Phase 3

A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
CompletedNCT01241552
Merck Sharp & Dohme LLCClostridium Difficile Infection
Start: 2011-10-10End: 2014-12-09Updated: 2018-09-05
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
CompletedNCT01513239
Merck Sharp & Dohme LLCClostridium Difficile Infection
Start: 2012-02-01End: 2015-05-22Updated: 2018-09-05

Related Papers

Predicted Bezlotoxumab Exposure in Patients Who Have Received a Hematopoietic Stem Cell Transplant.
2023-03-09
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
Clinical and Translational Science2021-10-2730 citations
Global Landscape of Clostridioides Difficile Phylogeography, Antibiotic Susceptibility, and Toxin Polymorphisms by Post-Hoc Whole-Genome Sequencing from the MODIFY I/II Studies.
2021-03-2220 citations
Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials
European Journal of Clinical Microbiology & Infectious Diseases2020-06-068 citations
Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
Open Forum Infectious Diseases2020-06-0122 citations
Genetic Association Reveals Protection against Recurrence of <i>Clostridium difficile</i> Infection with Bezlotoxumab Treatment.
2020-05-0610 citations
Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer
Open Forum Infectious Diseases2020-01-3011 citations
Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II
Clinical Infectious Diseases2019-12-1816 citations
Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.
2019-12-148 citations
Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection
Clinical Infectious Diseases2019-10-0124 citations
Assessment of Bezlotoxumab Immunogenicity
Clinical Pharmacology in Drug Development2019-08-143 citations
Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II
Open Forum Infectious Diseases2019-08-0110 citations
Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent <i>Clostridium difficile</i> Infection
Antimicrobial Agents and Chemotherapy2018-11-1622 citations
Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials
Open Forum Infectious Diseases2018-11-017 citations
Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
2018-09-0117 citations
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
Clinical Infectious Diseases2018-03-02200 citations
Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
Clinical Infectious Diseases2017-06-2220 citations
Bezlotoxumab for Prevention of Recurrent <i>Clostridium difficile</i> Infection
New England Journal of Medicine2017-01-25832 citations
Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach.
2016-06-18124 citations